Search for Clinical Trial Results

Sponsored By

Chronic Myelomonocytic Leukemia - 30 Studies Found

Status Study
Completed Study Name: Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Condition:
  • Myelodysplastic Syndrome
  • Chronic Myelomonocytic Leukemia
    • <
    Date: 2010-01-12
    Interventions:
    • Drug: Azacitidine 100 mg / m(2
Completed Study Name: Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Condition:
  • Chronic Myelomonocytic Leukemia
  • de Novo Myelodysplastic Syndrom
    Date: 2007-03-20
    Interventions: Drug: sunitinib malate Given orally Other Names:
Active, not recruiting Study Name: Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
Condition:
  • Anemia
  • Myelodysplastic Syndromes
  • Chr
    Date: 2012-11-27
    Interventions:
    • Drug: Sotatercept Sotatercept

Completed Study Name: SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)
Condition:
  • Myelofibrosis
  • Chronic Myelomonocytic Leukemia
  • Myelodysplastic Syndromes
  • Leukemia, Myelomonocytic, Chronic Date: 2015-11-18
    Interventions:
    • Drug: Azacitidine Azacitidine

Completed Study Name: Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia
Condition: Recurrent Chronic Myelomonocytic Leukemia
Date: 2025-11-04
Interventions: Undergo collection of blood samples
Completed Study Name: Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Condition: Chronic Myelomonocytic Leukemia
Date: 2025-11-04
Interventions: Undergo collection of blood and buccal samples
NOT_YET_RECRUITING Study Name: Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.
Condition: Chronic Myelomonocytic Leukemia
Date: 2025-11-04
Interventions: CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule der
COMPLETED Study Name: Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents
Condition: Refractory Chronic Myelomonocytic Leukemia
Date: 2025-11-04
Interventions: Given PO
COMPLETED Study Name: Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents
Condition: Refractory Chronic Myelomonocytic Leukemia
Date: 2025-11-04
Interventions: Given PO
<<< Previous